Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant cemiplimab + imiquimod + laser for high-risk resectable cutaneous basal cell carcinoma
2025-520698-38-00Phase 2Authorised
- Sponsor
- Instituto Oncológico Dr. Rosell
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and imiquimod in basal cell carcinoma (BCC), sponsored by Instituto Oncológico Dr. Rosell. Primary endpoints: Incidence of adverse events and treatment-related adverse events and Relapse-free survival rate at 3 years. Planned start Oct 2025; status: authorised.
02
Drugs
cemiplimabimiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2025-520698-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520698-38-00.